Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese firm's goal is to consolidate resources to enhance it's prescription drug pipeline, maximize Crestor (rosuvastatin) product value, and strengthen domestic marketing and overseas expansion.